视神经脊髓炎谱系障碍市场预计将在2036年前强劲扩张 DelveInsight-动脉网

Neuromyelitis Optica Spectrum Disorder Market Poised for Robust Expansion Through 2036

PR Newswire 等信源发布 2026-03-16 22:01



可切换为仅中文







The neuromyelitis optica spectrum disorder market size in the 7MM is expected to show positive growth during the forecast period (2026–2036), mainly attributed to the increasing prevalence of NMOSD, growing awareness, advancement in diagnostic techniques, and the launch of emerging therapies such as BAT4406F (Bio-Thera Solutions), Telitacicept (RC18) (RemeGen/Vor Bio), Divozilimab (BCD-132) (Biocad), and others, reports DelveInsight..

预计在预测期（2026-2036年）内，7MM的视神经脊髓炎谱系障碍市场规模将呈现正增长，主要归因于NMOSD患病率的增加、意识的提高、诊断技术的进步以及新兴疗法的推出，如BAT4406F（百奥泰生物制药）、Telitacicept (RC18)（荣昌生物/Vor Bio）、Divozilimab (BCD-132)（Biocad）等，DelveInsight报告称。

LAS VEGAS

拉斯维加斯

，

March 16, 2026

2026年3月16日

/PRNewswire/ -- Recently published Neuromyelitis Optica Spectrum Disorder Market Insights report includes a comprehensive understanding of current treatment practices, neuromyelitis optica spectrum disorder emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. .

/PRNewswire/ -- 近期发布的视神经脊髓炎谱系障碍市场洞察报告包含对当前治疗实践、视神经脊髓炎谱系障碍新兴药物、各疗法的市场份额以及2022年至2036年当前和预测的市场规模的全面理解，细分市场包括主要市场（美国、欧盟四国（德国、法国、意大利和西班牙）、英国和日本）。

Neuromyelitis Optica Spectrum Disorder Market Summary

视神经脊髓炎谱系障碍市场概况

The total neuromyelitis optica spectrum disorder treatment market size is expected to grow positively by 2036 in the leading markets.

预计到2036年，主要市场中的视神经脊髓炎谱系疾病治疗市场规模将实现正增长。

The United States accounted for the largest NMOSD treatment market size in 2025, compared to other major markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

2025年，美国的NMOSD治疗市场规模最大，相比之下，其他主要市场（包括欧盟四国（德国、法国、意大利和西班牙）、英国和日本）的规模较小。

The prevalence among females was

女性中的患病率为

9.48 per 100,000

每10万人中9.48人

, while among males it was

，而男性中则是

3.52 per 100,000

每10万人中3.52人

. The study observed a female-to-male ratio of approximately

。研究观察到男女比例约为

3.5:1

for NMOSD.

用于NMOSD。

Leading NMOSD companies, such as

领先的NMOSD公司，如

Bio-Thera Solutions, RemeGen, Vor Bio, Biocad,

百奥泰、荣昌生物、Vor Bio、Biocad

and others, are developing new NMOSD treatment drugs that can be available in the NMOSD market in the coming years.

并且其他公司，正在开发新的NMOSD治疗药物，这些药物可能在未来几年内进入NMOSD市场。

The promising NMOSD therapies in clinical trials include

临床试验中颇有前景的NMOSD疗法包括

BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132),

BAT4406F，泰利西普（RC18），迪沃奇单抗（BCD-132），

and others.

和其他人。

Discover what is the current and projected global NMOSD market size @

发现当前和预计的全球NMOSD市场规模 @

https://www.delveinsight.com/sample-request/neuromyelitis-optica-spectrum-disorder-nmosd-market

Key Factors Driving the Growth of the Neuromyelitis Optica Spectrum Disorder Market

推动视神经脊髓炎谱系障碍市场增长的关键因素

Improved Diagnostic Capabilities:

改进的诊断能力：

Advances in diagnostic tools, especially biomarker testing like AQP4-IgG and MOG-IgG assays, have significantly increased diagnostic accuracy and reduced delays in identifying NMOSD cases.

诊断工具的进步，特别是像AQP4-IgG和MOG-IgG检测这样的生物标志物测试，显著提高了诊断的准确性，并减少了识别NMOSD病例的延误。

Expansion of Targeted Therapeutic Options:

靶向治疗选择的扩展：

The launch and approval of novel biologic therapies, such as monoclonal antibodies and complement inhibitors, that specifically target immune pathways in NMOSD have transformed treatment approaches, driving higher adoption and market demand.

新型生物疗法（如单克隆抗体和补体抑制剂）的推出和获批，这些疗法专门靶向NMOSD中的免疫通路，已经改变了治疗方式，推动了更高的采用率和市场需求。

Launch of Emerging NMOSD Drugs:

新型NMOSD药物的上市：

The dynamics of the NMOSD market are expected to change in the coming years due to the launch of emerging therapies such as

由于新兴疗法的推出，预计未来几年NMOSD市场的动态将发生变化，例如

BAT4406F

(Bio-Thera Solutions),

百奥泰生物制药股份有限公司，

Telitacicept (RC18)

泰它西普 (RC18)

(RemeGen/Vor Bio),

（荣昌生物/沃贝奥生物），

Divozilimab (BCD-132)

迪沃齐利单抗 (BCD-132)

(Biocad), and others.

（Biocad）和其他公司。

Ramandeep Singh, Senior Consultant, Forecasting and Analytics at DelveInsight, said that the current treatment strategies for NMOSD encompass a multidisciplinary approach aimed at managing symptoms and enhancing quality of life. While there is no cure for NMOSD, interventions such as immunosuppressive therapy play a crucial role in the management of NMOSD.

德尔菲洞察公司预测与分析高级顾问拉曼迪普·辛格表示，目前NMOSD的治疗策略包括旨在管理症状和提高生活质量的多学科方法。虽然NMOSD尚无治愈方法，但免疫抑制疗法等干预措施在NMOSD的管理中起着至关重要的作用。

Recently approved therapies offer hope for future advancements in NMOSD treatment..

最近获批的疗法为NMOSD治疗的未来发展带来了希望。

Neuromyelitis Optica Spectrum Disorder Market Analysis

视神经脊髓炎谱系障碍市场分析

Current management strategies for NMOSD provide effective symptom control but do not offer a cure. Acute relapses are typically addressed using high-dose intravenous corticosteroids, such as methylprednisolone.

当前针对NMOSD的管理策略能够有效控制症状，但无法治愈。急性复发通常使用高剂量静脉注射糖皮质激素（如甲泼尼龙）进行处理。

Common long-term therapies include

常见的长期疗法包括

corticosteroids, azathioprine, mycophenolate mofetil, and rituximab, with azathioprine or mycophenolate mofetil

皮质类固醇、硫唑嘌呤、霉酚酸酯和利妥昔单抗，使用硫唑嘌呤或霉酚酸酯

often paired with low-dose steroids. For patients who do not respond adequately to intravenous corticosteroids during severe relapses, plasma exchange can be an effective alternative.

通常与低剂量类固醇联合使用。对于在严重复发期间对静脉注射皮质类固醇反应不佳的患者，血浆置换可以作为一种有效的替代方案。

In July 2025, NHS England introduced a national commissioning policy that recommends and funds the use of

2025年7月，英国国家医疗服务体系（NHS）英格兰引入了一项国家委托政策，该政策建议并资助使用

ACTEMRA (tocilizumab)

托珠单抗（ACTEMRA）

for NMOSD patients who are unable to tolerate or have not responded to earlier treatments.

对于无法耐受或未对先前治疗产生反应的NMOSD患者。

ACTEMRA is delivered through specialised neurology centres under NHS England. Although tocilizumab had previously been authorized by the MHRA for several inflammatory conditions, it had not been specifically approved for NMOSD in the UK until this policy.

ACTEMRA 由 NHS England 的专业神经科中心提供。尽管 tocilizumab 之前已获得 MHRA 批准用于多种炎症性疾病，但在英国，直到这一政策出台前，它并未被特别批准用于 NMOSD。

In the United States, FDA-approved treatments for NMOSD include

在美国，FDA批准的NMOSD治疗方法包括

ENSPRYNG, ULTOMIRIS

安适平，优特敏

, and others.

，以及其他。

Additionally, emerging pipeline therapies, such as

此外，新兴的管道疗法，如

BAT4406F

(Bio-Thera Solutions),

百奥泰生物制药

Telitacicept (RC18)

泰它西普 (RC18)

(RemeGen/Vor Bio),

（荣昌生物/沃贝奥生物），

Divozilimab (BCD-132)

迪沃齐利单抗 (BCD-132)

(Biocad), and others, are contributing to ongoing innovation in the NMOSD treatment landscape.

（Biocad）等公司正在为NMOSD治疗领域的持续创新做出贡献。

Neuromyelitis Optica Spectrum Disorder Competitive Landscape

视神经脊髓炎谱系障碍竞争格局

Some of the NMOSD drugs under development include

一些正在开发的NMOSD药物包括

BAT4406F

(Bio-Thera Solutions),

百奥泰生物制药股份有限公司，

Telitacicept (RC18)

泰乐赛普（RC18）

(RemeGen/Vor Bio),

（荣昌生物/沃贝奥生物），

Divozilimab (BCD-132)

迪沃齐利单抗 (BCD-132)

(Biocad), and others.

（Biocad）和其他。

Bio-Thera Solutions' BAT4406F

百奥泰生物的BAT4406F

is an investigational, Phase II glyco-engineered monoclonal antibody being studied in China. The treatment is designed to boost antibody-dependent cellular cytotoxicity (ADCC). As a type I anti-CD20 antibody, it promotes B-cell depletion through complement-dependent cytotoxicity while enhancing ADCC, and is currently under evaluation for autoimmune conditions such as NMOSD..

是一种正在中国研究的二期临床试验中的糖工程改造单克隆抗体。该治疗旨在增强抗体依赖性细胞毒性（ADCC）。作为一种I型抗CD20抗体，它通过补体依赖性细胞毒性促进B细胞清除，同时增强ADCC，目前正被评估用于治疗如NMOSD等自身免疫性疾病。

RemeGen/Vor Bio's Telitacicept (RC18)

荣昌生物/Vor Bio的泰勒他赛普（RC18）

is an innovative fusion protein developed for the treatment of autoimmune disorders. It is composed of the extracellular domain of the human TACI (transmembrane activator and calcium modulator and cyclophilin ligand interactor) receptor fused to the Fc portion of human IgG. Telitacicept is engineered to block two signaling molecules essential to B-cell maturation, BLyS and APRIL..

是一种用于治疗自身免疫性疾病的创新融合蛋白。它由人TACI（跨膜激活剂和钙调制器及亲环素配体相互作用因子）受体的胞外域与人IgG的Fc部分融合而成。泰利西普旨在阻断对B细胞成熟至关重要的两个信号分子：BLyS和APRIL。

Biocad's BCD-132 (divozilimab)

百欧卡的BCD-132（迪沃齐利单抗）

is a monoclonal antibody and a novel investigational therapy being developed for multiple sclerosis and other autoimmune conditions. Monoclonal antibodies are laboratory-engineered proteins modeled on the natural antibodies produced by the immune system, each designed to bind specifically to a particular target in the body..

是一种单克隆抗体，也是正在开发用于多发性硬化症和其他自身免疫性疾病的新型研究疗法。单克隆抗体是实验室设计的蛋白质，模仿免疫系统产生的天然抗体，每种抗体都旨在特异性结合身体中的特定目标。

For BCD-132, the target is the CD20 protein found on B cells. When BCD-132 attaches to CD20, it triggers the elimination of these B cells, lowering their numbers and thereby reducing immune activity associated with autoimmune diseases. Divozilimab's safety and effectiveness have been evaluated in preclinical animal studies, and clinical trials in humans are currently ongoing..

对于BCD-132，其靶点是B细胞上的CD20蛋白。当BCD-132附着于CD20时，会触发这些B细胞的清除，减少它们的数量，从而降低与自身免疫疾病相关的免疫活性。迪沃齐利单抗的安全性和有效性已在临床前动物研究中得到评估，目前针对人类的临床试验正在进行中。

The anticipated launch of these emerging therapies are poised to transform the NMOSD market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the NMOSD market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth..

这些新兴疗法的预期推出，有望在未来几年内改变NMOSD市场的格局。随着这些前沿疗法不断成熟并获得监管机构的批准，它们预计将重塑NMOSD市场，提供新的治疗标准，并为医疗创新和经济增长带来机遇。

Discover more about are new drugs upcoming in NMOSD pipeline @

了解更多关于NMOSD领域即将推出的新药信息 @

Neuromyelitis Optica Spectrum Disorder Drugs

视神经脊髓炎谱系疾病药物

What is Neuromyelitis Optica Spectrum Disorder?

什么是视神经脊髓炎谱系障碍？

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune condition in which the body's immune system mistakenly attacks the central nervous system, primarily targeting the optic nerves and spinal cord. This leads to episodes of optic neuritis, causing vision loss or eye pain, and transverse myelitis, which can result in limb weakness, sensory changes, or problems with bladder and bowel control.

视神经脊髓炎谱系障碍（NMOSD）是一种罕见的自身免疫性疾病，患者的免疫系统错误地攻击中枢神经系统，主要影响视神经和脊髓。这会导致视神经炎发作，引起视力丧失或眼痛，以及横贯性脊髓炎，可能导致肢体无力、感觉改变或膀胱和肠道控制问题。

NMOSD is often associated with antibodies against a protein called aquaporin-4 (AQP4), which helps distinguish it from similar conditions like multiple sclerosis. Because attacks can be severe and cause lasting disability, early diagnosis and long-term treatment to prevent relapses are essential for managing the disorder effectively..

NMOSD 通常与针对一种名为水通道蛋白 4 (AQP4) 的蛋白质的抗体有关，这有助于将其与类似多发性硬化症的病症区分开来。由于发作可能很严重并导致长期残疾，因此早期诊断和长期治疗以预防复发对于有效管理该疾病至关重要。

Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

视神经脊髓炎谱系障碍流行病学细分

The NMOSD epidemiology section provides insights into the historical and current NMOSD patient pool and forecasted trends for the leading markets. The diagnosed prevalence rate of NMOSD is estimated at nearly

NMOSD流行病学部分提供了对历史和当前NMOSD患者群体的洞察，并预测了主要市场的趋势。NMOSD的诊断患病率估计接近

1.5 per 100,000

每10万人中1.5人

population. Between

人口。之间

70–80%

70%-80%

of NMOSD patients will have anti-AQP4 antibodies.

NMOSD患者将具有抗AQP4抗体。

The NMOSD treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:

NMOSD治疗市场报告提供了2022年至2036年研究期间主要市场的流行病学分析，细分如下：

Total Prevalent Cases of NMOSD

NMOSD的总流行病例数

Total Diagnosed Prevalent Cases of NMOSD

NMOSD的总诊断患病数

Gender-specific Diagnosed Prevalent Cases of NMOSD

性别特异的NMOSD确诊病例数

Treated Cases of NMOSD

NMOSD治疗病例

Neuromyelitis Optica Spectrum Disorder Market Report Metrics

视神经脊髓炎谱系障碍市场报告指标

Details

详细信息

Study Period

学习期

2022–2036

Coverage

覆盖范围

7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

7MM［美国、欧盟4国（德国、法国、意大利和西班牙）、英国和日本］。

Neuromyelitis Optica Spectrum Disorder Epidemiology Segmentation

视神经脊髓炎谱系障碍流行病学细分

Total Prevalent Cases of NMOSD, Total Diagnosed Prevalent Cases of NMOSD, Gender-specific Diagnosed Prevalent Cases of NMOSD, and Treated Cases of NMOSD

NMOSD的总流行病例数、NMOSD的总确诊流行病例数、NMOSD的性别特定确诊流行病例数以及NMOSD的治疗病例数

Key Neuromyelitis Optica Spectrum Disorder Companies

主要视神经脊髓炎谱系疾病公司

Bio-Thera Solutions, RemeGen, Vor Bio, Biocad, Genentech, Chugai Pharmaceuticals, AstraZeneca, Alexion, and others

百奥泰生物、荣昌生物、Vor Bio、Biocad、基因泰克、中外制药、阿斯利康、Alexion等公司

Key Neuromyelitis Optica Spectrum Disorder Therapies

关键的视神经脊髓炎谱系疾病疗法

BAT4406F, Telitacicept (RC18), Divozilimab (BCD-132), ENSPRYNG, ULTOMIRIS, SOLIRIS, and others

BAT4406F、泰利西普（RC18）、地沃单抗（BCD-132）、ENSPRYNG、ULTOMIRIS、SOLIRIS 等等

Scope of the

范围

Neuromyelitis Optica Spectrum Disorder

视神经脊髓炎谱系障碍

Market Report

市场报告

Therapeutic Assessment:

治疗评估：

Neuromyelitis Optica Spectrum Disorder current marketed and emerging therapies

视神经脊髓炎谱系障碍当前市场上的和新兴的疗法

Neuromyelitis Optica Spectrum Disorder

视神经脊髓炎谱系障碍

Market Dynamics:

市场动态：

Key Market Forecast Assumptions of Emerging Neuromyelitis Optica Spectrum Disorder Drugs and Market Outlook

新兴视神经脊髓炎谱系疾病药物的关键市场预测假设与市场展望

Competitive Intelligence Analysis:

竞争情报分析：

SWOT analysis and Market entry strategies

SWOT分析与市场进入策略

Unmet Needs, KOL's views, Analyst's views, Neuromyelitis Optica Spectrum Disorder Market Access and Reimbursement

未满足的需求、关键意见领袖的观点、分析师的观点、视神经脊髓炎谱系障碍市场准入和报销

Download the report to understand what market trends are shaping NMOSD over the next decade @

下载报告以了解未来十年内影响NMOSD的市场趋势 @

Neuromyelitis Optica Spectrum Disorder Market Analysis

视神经脊髓炎谱系障碍市场分析

Table of Contents

Neuromyelitis Optica Spectrum Disorder Market Key Insights

视神经脊髓炎谱系障碍市场关键洞察

Neuromyelitis Optica Spectrum Disorder Market Report Introduction

视神经脊髓炎谱系障碍市场报告介绍

NMOSD Market Overview at a Glance

NMOSD市场概况一览

3.1

Market Share (%) Distribution of NMOSD by Therapies in the 7MM in 2025

2025年7MM中NMOSD按疗法划分的市场份额（%）分布

3.2

Market Share (%) Distribution of NMOSD by Therapies in the 7MM in 2036

2036年七大市场NMOSD按疗法划分的市场份额（%）分布

Methodology

方法论

Executive Summary

执行摘要

Key Events

关键事件

Disease Background and Overview: NMOSD

疾病背景与概述：NMOSD

7.1

Introduction

介绍

7.2

Classification

分类

7.3

Causes

原因

7.4

Signs and Symptoms

体征与症状

7.5

Pathophysiology

病理生理学

7.6

Clinical features

临床特征

7.7

Diagnosis

诊断

7.8

Treatment and Management

治疗与管理

Epidemiology and Patient Population of NMOSD in the 7MM

7MM中NMOSD的流行病学和患者人群

8.1

Key Findings

主要发现

8.2

Assumptions and Rationale

假设与理由

8.3

Total Prevalent Cases of NMOSD in the 7MM

7MM中NMOSD的总流行病例数

8.4

Total Diagnosed Prevalent Cases of NMOSD in the 7MM

7MM中NMOSD的总诊断患病数

8.5

The US

美国

8.5.1

Total Prevalent Cases of NMOSD

NMOSD的总流行病例数

8.5.2

Total Diagnosed Prevalent Cases of NMOSD

NMOSD的总诊断患病数

8.5.3

Gender-specific Diagnosed Prevalent Cases of NMOSD

性别特异的NMOSD确诊病例数

8.5.4

Treated Cases of NMOSD

NMOSD的治疗病例

8.6

EU4 and the UK

EU4 和英国

8.7

Japan

日本

NMOSD Patient Journey

NMOSD患者旅程

Marketed NMOSD Therapies

已上市的NMOSD疗法

10.1

Key Cross Competition

关键交叉竞争

10.2

ENSPRYNG: Genentech/Chugai Pharmaceuticals

ENSPRYNG：基因泰克/中外制药

10.2.1

Product Description

产品描述

10.2.2

Product Profile

产品概况

10.2.3

Other Developmental Activities

其他开发活动

10.2.4

Clinical Trials Information

临床试验信息

10.2.5

Safety and Efficacy

安全性与有效性

10.3

ULTOMIRIS: AstraZeneca

ULTOMIRIS：阿斯利康

10.4

SOLIRIS: Alexion/AstraZeneca

SOLIRIS：Alexion/阿斯利康

List to be continued in the final report.

最终报告中将继续列出清单。

Emerging NMOSD Therapies

新兴的NMOSD疗法

11.1

Key Cross Competition

关键交叉竞争

11.2

BAT4406F: Bio-Thera Solutions

百奥泰生物科技

11.2.1

Drug Description

药品说明书

11.2.2

Product Profile

产品概况

11.2.3

Other Developmental Activities

其他开发活动

11.2.4

Clinical Trials Information

临床试验信息

11.2.5

Safety and Efficacy

安全性与有效性

11.3

Telitacicept (RC18): RemeGen/Vor Bio

泰利西普 (RC18): 荣昌生物/Vor Bio

List to be continued in the final report.

清单将在最终报告中继续。

NMOSD: Market Analysis

NMOSD：市场分析

12.1

Key Findings

主要发现

12.2

Key Neuromyelitis Optica Spectrum Disorder Market Forecast Assumptions

关键的视神经脊髓炎谱系障碍市场预测假设

12.3

Neuromyelitis Optica Spectrum Disorder Market Outlook

视神经脊髓炎谱系疾病市场展望

12.4

Conjoint Analysis

联合分析

12.5

Total Market Size of NMOSD in the 7MM

7MM中NMOSD的总市场规模

12.6

Market Size of NMOSD by Therapies in the 7MM

七大市场中NMOSD按疗法划分的市场规模

12.7

The US Neuromyelitis Optica Spectrum Disorder Market

美国视神经脊髓炎谱系障碍市场

12.8.1

Total Market Size of NMOSD

NMOSD总市场容量

12.8.2

Market size of NMOSD by Therapies

按疗法划分的NMOSD市场规模

12.8

EU4 and the UK Neuromyelitis Optica Spectrum Disorder Market

欧盟四国和英国视神经脊髓炎谱系疾病市场

12.9

Japan Neuromyelitis Optica Spectrum Disorder Market

日本视神经脊髓炎谱系障碍市场

12.9.1

Total Market Size of NMOSD

NMOSD总市场容量

12.9.2

Market size of NMOSD by Therapies

按疗法划分的NMOSD市场规模

Key Opinion Leaders' Views on NMOSD

关键意见领袖对NMOSD的看法

NMOSD Market SWOT Analysis

NMOSD市场SWOT分析

NMOSD Market Unmet needs

NMOSD市场未满足的需求

Market Access and Reimbursement

市场准入与报销

16.1

The US

美国

16.2

In EU4 and the UK

在欧盟4国和英国

16.3

Japan

日本

Acronyms and Abbreviations

缩略语和简称

Bibliography

参考文献

Neuromyelitis Optica Spectrum Disorder Market Report Methodology

视神经脊髓炎谱系障碍市场报告方法论

Related Reports